Evidence Based Management of Acute Biliary Pancreatitis

Sponsor
Zagazig University (Other)
Overall Status
Completed
CT.gov ID
NCT04615702
Collaborator
(none)
30
1
24
1.3

Study Details

Study Description

Brief Summary

This study aims to assess the outcome of standardized evidence-based care to all patients with acute biliary pancreatitis treated at surgery department, Zagazig University hospitals during the period from may, 2017 to may 2019.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: serum lipase or amylase
  • Device: ultrasound
  • Device: CT
  • Diagnostic Test: Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.
  • Device: EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)
  • Drug: Ringer lactate
  • Combination Product: NSAID / paracetamol +/- opiates+/- epidural analgesia
  • Combination Product: Quinolones + Metronidazole /Carbapenems ± Metronidazole
  • Dietary Supplement: Fresubin 2Kcal fiber drink
  • Device: nasogastric tube
  • Procedure: retroperitoneal necrosectomy
  • Procedure: open necrosectomy
  • Procedure: Endoscopic transmural cystogastrostomy
  • Procedure: open cystogastrostomy
  • Procedure: percutaneous catheter drainage (PCD) for infected necrosis
  • Procedure: Endoscopic ultrasound (EUS) guided aspiration for infected necrosis

Detailed Description

Acute pancreatitis (AP) is one of the most important gastrointestinal disorders causing emotional and physical human burden . The annual incidence worldwide for AP is 4.9-73.4 cases per 100,000 people and the overall mortality rate is 4 to 8%, which increases to 33% in patients with infected necrosis. AP is diagnosed when two of three criteria are fulfilled: typical abdominal pain of AP, more than three times elevated serum amylase/lipase level and signs of AP on imaging.

It is necessary to clarify the etiology of AP promptly. The diagnosis of gallstones, as the leading cause for AP, should have the top priority as that will direct the treatment policy. Long standing alcohol consumption and gallstones disease incriminated in the majority of cases with AP. Small common bile duct stones, in particular, are the cause of AP in approximately 32 to 40% of cases. In 10-30% of cases, the cause is unknown, so studies have suggested that up to 70% of cases of idiopathic pancreatitis are secondary to biliary microlithiasis.

The pathogenesis of biliary AP has been intensively investigated. Many theories explain how gallstones can trigger AP. The predominant theories include common pathway theory and gallstone migration theory. In general, AP occurs when intracellular protective mechanisms fail to prevent trypsinogen activation or reduce trypsin activity.

It is important that management of such potentially life threatening condition to be guided by an evidence-based approach. After comparing the Japanese (JPN) Guidelines 2015 and its former edition 2010 with the other two guidelines, International Association of Pancreatology/American Pancreas Association guidelines (IAP/APA), 2013 and American College of Gastroenterology (ACG), 2013, the JPN Guidelines, 2015 proved to be the highest quality regarding its systematic literature review prepared by the meta-analysis team, including the grading of recommendations and providing pancreatitis bundles.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
30 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Evidence Based Management of Acute Biliary Pancreatitis
Actual Study Start Date :
May 15, 2017
Actual Primary Completion Date :
May 15, 2019
Actual Study Completion Date :
May 15, 2019

Arms and Interventions

Arm Intervention/Treatment
application of recent guidelines in the management of acute biliary pancreatitis

all patients subjected to the following: Confirmation of the diagnosis of acute pancreatitis, Diagnosis of the cause either biliary or not, Severity scoring and Evidence based management regarding Initial management, Intervention as indicated, Prevention of recurrence and Follow up

Diagnostic Test: serum lipase or amylase
Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis Acute pancreatitis is diagnosed when two of three criteria are present including: Clinically (abdominal pain consistent with acute pancreatitis), Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) Imaging criteria of acute pancreatitis

Device: ultrasound
helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)

Device: CT
helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis

Diagnostic Test: Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.
help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis

Device: EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)
helpful in idiopathic acute pancreatitis diagnosis

Drug: Ringer lactate
The initial infusion rate for mild cases : For patients without dehydration is (130-150mL/h). In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload. The initial infusion rate for both severe cases : For patients without dehydration is (130-150mL/h). In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target A mean arterial pressure of 65mmHg or more, Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters.
Other Names:
  • hartmann's solution
  • Combination Product: NSAID / paracetamol +/- opiates+/- epidural analgesia
    Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h. Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia
    Other Names:
  • NSAID (Diclofenac sodium) paracetamol (perfalgan drip) Opiates (Pethidine)
  • Combination Product: Quinolones + Metronidazole /Carbapenems ± Metronidazole
    Mild attack: no antibiotic prophylaxis administered. Severe attack: Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset. Duration: Not more than 2 weeks Antibiotics given: Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h b. Therapeutic (in cases with pancreatic or extrapancreatic infections) In case of pancreatic infection, Carbapenems ± metronidazole were given.
    Other Names:
  • Quinolones (ciprofloxacin) Metronidazole (flagyl) Carbapenems (Imipenem)
  • Dietary Supplement: Fresubin 2Kcal fiber drink
    Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications. Route: Nasogastric tube Nutrients: Polymeric feeding formula Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml) Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion The nutrition started with small amount and increased gradually over 16hrs Infusion rate ꞊ Total caloric requirements / 16hrs
    Other Names:
  • polymeric feeding formula
  • Device: nasogastric tube
    in case of ileus or vomiting

    Procedure: retroperitoneal necrosectomy
    General anesthesia , Supine position with 30 degree tilt towards the right side A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially Then, aspiration is done from the possible collection. After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously. At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures

    Procedure: open necrosectomy
    Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain. The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis.

    Procedure: Endoscopic transmural cystogastrostomy
    for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance. The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis

    Procedure: open cystogastrostomy
    for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa. First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way.

    Procedure: percutaneous catheter drainage (PCD) for infected necrosis
    PCD The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F. After placement of the percutaneous catheter, aspirate was sent for microbiological assessment The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection

    Procedure: Endoscopic ultrasound (EUS) guided aspiration for infected necrosis
    endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual

    Outcome Measures

    Primary Outcome Measures

    1. success rate of minimally invasive techniques (percutaneaous catheter drainage, endoscopic approach and retroperitoneal approach) in cases with infected walled off necrosis [immediately following intervention to 6 weeks following intervention]

      Data were tabulated and statistically analyzed in terms of percentages Success of the intervention means patient condition improves [clinical (vital signs) , laboratory (CBC, kidney and liver function tests) and radiological improvement (no residual collection in CT)] and that there is no need for further intervention to control the disease till patient discharge

    2. rate of complications of minimally invasive techniques used in the management of cases with infected walled off necrosis including bleeding, fistula, wound infection, incisional hernia [up to 6 months following intervention]

      Data were tabulated and statistically analyzed in terms of percentages

    3. Mortality rate of acute biliary pancreatitis in the study period [from admission to 6 months following admission]

      Data were tabulated and statistically analyzed in terms of percentages

    4. length of hospital stay of mild and severe cases with acute biliary pancreatitis [up to 6 months]

      Data were tabulated and statistically analyzed in terms of frequencies length of hospital stay in days

    Secondary Outcome Measures

    1. age of cases with acute biliary pancreatitis in Sharqia in years [at admission]

      Data were tabulated and statistically analyzed in terms of mean

    2. Sex of cases with acute biliary pancreatitis in Sharqia (Males and females) [at admission]

      Data were tabulated and statistically analyzed in terms of percentages

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • all cases with acute biliary pancreatitis
    Exclusion Criteria:
    • all cases with non biliary pancreatitis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zagazig University Faculty of Human Medicine Zagazig Egypt 44519

    Sponsors and Collaborators

    • Zagazig University

    Investigators

    • Principal Investigator: yasmine Hegab, zagazig university faculty of human medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    yasmine Hany Hegab, principal investigator, Zagazig University
    ClinicalTrials.gov Identifier:
    NCT04615702
    Other Study ID Numbers:
    • acute panreatitis guidelines
    First Posted:
    Nov 4, 2020
    Last Update Posted:
    Nov 5, 2020
    Last Verified:
    Nov 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by yasmine Hany Hegab, principal investigator, Zagazig University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 5, 2020